Emil Lou
University of Minnesota
CancerInternal medicinePathologyOncologyCellVirusTumor microenvironmentChemotherapyBevacizumabOvarian cancerKRASIn patientCancer researchColorectal cancerClinical trialMedicineCell cultureOncolytic virusBiologyCell biology
Publications 159
#1Nuttavut Sumransub (UMN: University of Minnesota)
#2Kornpong Vantanasiri (UMN: University of Minnesota)H-Index: 3
Last. Emil Lou (UMN: University of Minnesota)H-Index: 27
view all 4 authors...
Abstract Immunotherapy in the metastatic setting has drastically altered the landscape of treatment for various types of malignancy, including colorectal cancer. The category of immune checkpoint inhibitors has especially emerged as a class of therapy predicated on a more comprehensive understanding of immune cell-cancer cell regulation and evolution of the tumor microenvironment over time. Strategies including adoptive cellular therapies, tumor vaccines, and antibodies have also demonstrated ab...
#1Shivika Prasanna (MU: University of Missouri)
#2Naveen Premnath (UTSW: University of Texas Southwestern Medical Center)H-Index: 2
Last. Muhammad Shaalan Beg (UTSW: University of Texas Southwestern Medical Center)H-Index: 19
view all 13 authors...
322Background: Natural language processing (NLP) algorithms can be leveraged to better understand prevailing themes in healthcare conversations. Sentiment analysis, an NLP technique to analyze and ...
#1Valentino Clemente (UMN: University of Minnesota)
#2Andrew C. Nelson (UMN: University of Minnesota)H-Index: 14
Last. Martina Bazzaro (UMN: University of Minnesota)H-Index: 18
view all 10 authors...
Abstract null Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in glutamine metabolism that is overexpressed in several human cancers. A first-in-class inhibitor of GLS1, called CB839 (Telaglenastat), has been investigated in several clinical trials, with promising results. The first clinical trial of CB839 in ...
#1Hiroyuki AraiH-Index: 6
#2Yasmine BacaH-Index: 3
Last. Emil LouH-Index: 27
view all 19 authors...
#1Guru TrikudanathanH-Index: 20
#2Emil Lou (UMN: University of Minnesota)H-Index: 27
Last. Shounak Majumder (Mayo Clinic)H-Index: 13
view all 4 authors...
PURPOSE OF REVIEW Pancreatic ductal adenocarcinoma (PDAC) is third leading cause of cancer death in the United States, a lethal disease with no screening strategy. Although diagnosis at an early stage is associated with improved survival, clinical detection of PDAC is typically at an advanced symptomatic stage when best in class therapies have limited impact on survival. RECENT FINDINGS In recent years this status quo has been challenged by the identification of novel risk factors, molecular mar...
#4Matthew Johnson (UMN: University of Minnesota)H-Index: 1
PD-1 acts as a negative regulator of T cell-mediated immune responses in the setting of persistent antigen expression, including cancer and chronic pathogen infections. Antibody-mediated blockade of the PD-1/PD-L1 axis benefits a subset of patients with highly immunogenic malignancies; however, many patients fail to respond due to a requirement for expression of the cell surface ligand PD-L1 within the tumor microenvironment. CISH is a member of a new class of intra-cellular immune checkpoint mo...
#1Jingyuan Wang (SC: University of Southern California)H-Index: 2
#2Joanne XiuH-Index: 19
Last. H. J. Lenz (SC: University of Southern California)H-Index: 23
view all 22 authors...
PURPOSE The impact of molecular alterations on PD-L1 combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas (GEAs). We aimed to characterize genomic features of tumors with different CPSs in GEAs. PATIENTS AND METHODS Genomic alterations of 2,518 GEAs were compared in three groups (PD-L1 CPS≥10, high; CPS=1-9, intermediate; CPS<1, low) using next-generation sequencing. We assessed the impact of gene mutations on the efficacy of immune checkpoint inhibitors (ICIs) a...
#1Akshat SarkariH-Index: 2
Last. Emil LouH-Index: 27
view all 9 authors...
#1Paul W. SperdutoH-Index: 28
#2Emil Lou (UMN: University of Minnesota)H-Index: 27